HK1252582B - 具有增强的細胞毒性的修飾的天然殺傷細胞和天然殺傷細胞系 - Google Patents

具有增强的細胞毒性的修飾的天然殺傷細胞和天然殺傷細胞系

Info

Publication number
HK1252582B
HK1252582B HK18111896.2A HK18111896A HK1252582B HK 1252582 B HK1252582 B HK 1252582B HK 18111896 A HK18111896 A HK 18111896A HK 1252582 B HK1252582 B HK 1252582B
Authority
HK
Hong Kong
Prior art keywords
natural killer
cell lines
increased cytotoxicity
killer cells
modified
Prior art date
Application number
HK18111896.2A
Other languages
English (en)
Other versions
HK1252582A1 (zh
Inventor
Michael Eamon Peter O'dwyer
Original Assignee
Onkimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1603655.0A external-priority patent/GB201603655D0/en
Priority claimed from GBGB1610164.4A external-priority patent/GB201610164D0/en
Application filed by Onkimmune Ltd filed Critical Onkimmune Ltd
Publication of HK1252582A1 publication Critical patent/HK1252582A1/zh
Publication of HK1252582B publication Critical patent/HK1252582B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
HK18111896.2A 2015-07-29 2018-09-17 具有增强的細胞毒性的修飾的天然殺傷細胞和天然殺傷細胞系 HK1252582B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15178899 2015-07-29
GBGB1603655.0A GB201603655D0 (en) 2016-03-02 2016-03-02 Modified natural killer cells and natural killer cell lines having increased cytotoxicity
GB201605457 2016-03-31
GBGB1610164.4A GB201610164D0 (en) 2016-06-10 2016-06-10 Modified natural killer cells and natural killer cell lines having increased cytoxicity
PCT/EP2016/068001 WO2017017184A1 (en) 2015-07-29 2016-07-28 Modified natural killer cells and natural killer cell lines having increased cytotoxicity

Publications (2)

Publication Number Publication Date
HK1252582A1 HK1252582A1 (zh) 2019-05-31
HK1252582B true HK1252582B (zh) 2020-02-07

Family

ID=56683913

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111896.2A HK1252582B (zh) 2015-07-29 2018-09-17 具有增强的細胞毒性的修飾的天然殺傷細胞和天然殺傷細胞系

Country Status (13)

Country Link
US (3) US10034925B2 (zh)
EP (6) EP3971284B1 (zh)
JP (3) JP6974681B2 (zh)
KR (1) KR20180028530A (zh)
CN (3) CN116064401A (zh)
AU (2) AU2016300128B2 (zh)
BR (1) BR112018001660A2 (zh)
CA (2) CA2993796C (zh)
DK (3) DK3317401T3 (zh)
ES (5) ES2890859T3 (zh)
HK (1) HK1252582B (zh)
MX (2) MX2018001074A (zh)
WO (1) WO2017017184A1 (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
ES2890859T3 (es) 2015-07-29 2022-01-24 Onk Therapeutics Ltd Células asesinas naturales modificadas y líneas de células asesinas naturales que tienen citotoxicidad aumentada
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN110248669B (zh) 2016-12-09 2023-09-08 昂克医疗有限公司 工程化天然杀伤细胞及其用途
WO2018129346A1 (en) * 2017-01-06 2018-07-12 Nantkwest, Inc. Genetically modified nk-92 cells with decreased cd96/tigit expression
CA3052473A1 (en) * 2017-02-09 2018-08-16 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and compositions and methods thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
DE102017002645A1 (de) * 2017-03-17 2018-09-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Bestrahlung von Säugetierzellen mit Elektronenstrahlen und/oder Röntgenstrahlen
CA3069557A1 (en) 2017-07-21 2019-01-24 Cellectis Engineered immune cells resistant to tumor microoenvironment
WO2019016360A1 (en) * 2017-07-21 2019-01-24 Cellectis MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
EP3714040A1 (en) 2017-11-24 2020-09-30 ONK Therapeutics Limited Modified natural killer cells and natural killer cell lines targetting tumour cells
JP2021523725A (ja) * 2018-05-16 2021-09-09 リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタルＲｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ａｔ Ｎａｔｉｏｎｗｉｄｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｃａｓ９リボ核タンパク質を使用したノックアウト初代および増殖ヒトｎｋ細胞の生成
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
CN108743595B (zh) * 2018-06-08 2020-11-27 厦门诺康得生物科技有限公司 一种nk细胞免疫检查点抑制剂及其制备方法
WO2020168300A1 (en) * 2019-02-15 2020-08-20 Editas Medicine, Inc. Modified natural killer (nk) cells for immunotherapy
CN109908155A (zh) * 2019-03-11 2019-06-21 上海中医药大学 丹参酮ⅱa的药物用途
KR102292657B1 (ko) 2019-03-15 2021-08-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
WO2020189942A1 (ko) * 2019-03-15 2020-09-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
US20220143089A1 (en) * 2019-03-21 2022-05-12 Onk Therapeutics Limited Modified immune effector cells with increased resistance to cell death
RU2731293C1 (ru) 2019-04-12 2020-09-01 Игорь Петрович Белецкий Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний
CN109970869A (zh) * 2019-04-12 2019-07-05 南京卡提医学科技有限公司 一种靶向人trail死亡受体的嵌合受体配体及其应用
EP3789485A1 (en) 2019-09-06 2021-03-10 ONK Therapeutics Limited Cellular therapies for cancer
EP4038190A1 (en) 2019-10-03 2022-08-10 Artisan Development Labs, Inc. Crispr systems with engineered dual guide nucleic acids
CN111849896B (zh) * 2020-07-31 2022-07-01 广东昭泰体内生物医药科技有限公司 一种car-nk细胞培养基及其应用
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
JP2024522756A (ja) 2021-06-18 2024-06-21 オーエヌケイ セラピューティクス リミテッド ダブルノックアウトナチュラルキラー細胞
EP4370676A2 (en) 2021-06-18 2024-05-22 Artisan Development Labs, Inc. Compositions and methods for targeting, editing or modifying human genes
CN113684180B (zh) * 2021-08-31 2023-05-26 山东大学第二医院 一种提高骨髓瘤杀伤活性的nk细胞制备方法
CN114544971B (zh) * 2022-02-22 2024-08-30 广东省科学院动物研究所 一种功能蛋白活性的检测方法
WO2023167882A1 (en) 2022-03-01 2023-09-07 Artisan Development Labs, Inc. Composition and methods for transgene insertion
CN114796483B (zh) * 2022-06-28 2022-11-08 北京大学 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物
EP4353741A1 (en) 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells
WO2024100203A1 (en) 2022-11-10 2024-05-16 Onk Therapeutics Limited Combined therapies using immunomodulating drugs
CN116590237B (zh) * 2023-05-29 2023-10-31 上海贝斯昂科生物科技有限公司 一种遗传修饰的自然杀伤细胞及其制备和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE531789T1 (de) 2000-06-30 2011-11-15 Univ Louisville Res Found Zellmembranenveränderung
CA2388441A1 (en) 2002-06-10 2003-12-10 Wei-Ping Min Immunomodulation using rna interference
EP1781777A1 (en) * 2004-07-02 2007-05-09 Avaris AB Method for the genetic activation of cells and uses of said cells
CA3052445C (en) * 2004-07-10 2023-08-22 Kerry S. Campbell Genetically modified human natural killer cell lines
EP1621550A1 (en) * 2004-07-29 2006-02-01 Dompé S.P.A. Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
EP2595637B1 (en) 2010-07-22 2017-11-01 Cellect Biotherapeutics Ltd. Regulatory immune cells with enhanced targeted cell death effect
EP3763810A3 (en) * 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
AU2014223344A1 (en) * 2013-02-27 2015-10-01 Massachusetts Institute Of Technology T cell balance gene expression, compositions of matters and methods of use thereof
WO2015012145A1 (ja) 2013-07-25 2015-01-29 株式会社ブリヂストン 防振装置
CA2926698C (en) * 2013-10-15 2021-06-22 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
EP3593812A3 (en) * 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
CA2945335A1 (en) 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2016044605A1 (en) * 2014-09-17 2016-03-24 Beatty, Gregory Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
MX2017012407A (es) 2015-03-27 2018-03-07 Harvard College Celulas t modificadas y métodos para hacer y usar las mismas.
EP3317399B1 (en) * 2015-06-30 2024-06-26 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
CN109476722A (zh) * 2015-07-21 2019-03-15 诺华股份有限公司 用于改善免疫细胞的功效和扩张的方法
ES2890859T3 (es) * 2015-07-29 2022-01-24 Onk Therapeutics Ltd Células asesinas naturales modificadas y líneas de células asesinas naturales que tienen citotoxicidad aumentada

Also Published As

Publication number Publication date
ES2701338T3 (es) 2019-02-21
ES2890859T3 (es) 2022-01-24
BR112018001660A2 (pt) 2018-09-18
US20180326029A1 (en) 2018-11-15
AU2016300128A1 (en) 2018-02-22
JP2018522592A (ja) 2018-08-16
EP3828266A1 (en) 2021-06-02
AU2016300128B2 (en) 2022-03-17
EP3421590A1 (en) 2019-01-02
CN108026512A (zh) 2018-05-11
EP3878951A1 (en) 2021-09-15
US10034925B2 (en) 2018-07-31
MX2020010014A (es) 2020-10-14
US10960064B2 (en) 2021-03-30
ES2939084T3 (es) 2023-04-18
ES2970269T3 (es) 2024-05-27
EP3971284A1 (en) 2022-03-23
DK3421590T3 (da) 2021-10-04
CA2993796A1 (en) 2017-02-02
JP2021178824A (ja) 2021-11-18
JP2021169473A (ja) 2021-10-28
EP3317401B1 (en) 2018-10-03
RU2018104871A (ru) 2019-08-28
DK3317401T3 (da) 2019-01-02
HK1252582A1 (zh) 2019-05-31
JP6974681B2 (ja) 2021-12-01
KR20180028530A (ko) 2018-03-16
EP3828266B1 (en) 2022-11-23
WO2017017184A1 (en) 2017-02-02
EP3317401A1 (en) 2018-05-09
CA2993796C (en) 2024-02-20
JP7359346B2 (ja) 2023-10-11
RU2018104871A3 (zh) 2020-08-17
EP3971284B1 (en) 2023-11-08
CN108026512B (zh) 2022-09-16
MX2018001074A (es) 2018-11-12
EP3421590B1 (en) 2021-07-14
CN116064400A (zh) 2023-05-05
EP3434762A1 (en) 2019-01-30
CN116064401A (zh) 2023-05-05
AU2022203339A1 (en) 2022-06-09
US20170157230A1 (en) 2017-06-08
DK3434762T3 (da) 2021-06-07
EP3434762B1 (en) 2021-03-17
US20210138051A1 (en) 2021-05-13
ES2876938T3 (es) 2021-11-15
CA3156128A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
HK1252582B (zh) 具有增强的細胞毒性的修飾的天然殺傷細胞和天然殺傷細胞系
IL258666A (en) Natural killer cells and ilc3 cells and their use
IL253248A0 (en) Natural killer cells and their uses
HK1245080A1 (zh) 自然殺傷細胞的方法和組合物
SG11201609118RA (en) Modified natural killer cells and uses thereof
SG10201912825XA (en) Genetically modified cells and uses thereof
EP3207147A4 (en) Bipartite and tripartite signaling immune cells
PL3215166T3 (pl) Zmiana ekspresji genów w limfocytach car-t i ich zastosowanie
IL269334A (en) Improved compositions of t cells and methods
PT3191284T (pt) Células e módulos fotovoltaicos encapsulados
ZA201607022B (en) Encoded cells and cell arrays
IL259202A (en) Modified immune cells and their use
GB201704953D0 (en) Natural killer cells
PT3589728T (pt) Células assassinas naturais
HK1259030A1 (zh) 具有抗趨除特性的修飾的天然殺傷細胞及其用途
GB201603655D0 (en) Modified natural killer cells and natural killer cell lines having increased cytotoxicity
GB201610164D0 (en) Modified natural killer cells and natural killer cell lines having increased cytoxicity
AU2015904935A0 (en) Genetically modified cells and uses thereof - II
GB201616232D0 (en) Novel cell line and uses thereof
AU2015904933A0 (en) Genetically modified cells and uses thereof
GB201506451D0 (en) Improvements in and relating to devices
TWM490663U (en) Solar cell and back side electrode structure thereof
IL236273A0 (en) Cells and battery organizers
GB201420709D0 (en) Electrochemical cells and components thereof